This compound is primarily utilized in the field of targeted protein degradation, particularly in the development of PROTACs (Proteolysis Targeting Chimeras). It serves as a key component in designing molecules that can selectively degrade disease-causing proteins by recruiting E3 ubiquitin ligases, such as VHL (Von Hippel-Lindau), to tag the target proteins for proteasomal destruction. Its application is significant in cancer research, where it helps in degrading oncogenic proteins that are otherwise difficult to target with traditional small-molecule inhibitors. Additionally, it is explored in neurodegenerative diseases and other conditions driven by aberrant protein accumulation. Its role in advancing precision medicine and drug discovery is notable, offering a novel approach to tackling previously undruggable targets.